| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FIL1; FIL1D; IL1F5; IL1L1; PSORP; IL1HY1; IL1RP3; IL36RA; IL-36Ra; PSORS14; FIL1(DELTA) |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL36RN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL36RN或相关抗体的3篇参考文献，按简单格式整理：
1. **文献名称**: *"Anti-Interleukin-36 Receptor Antibodies as a Novel Therapeutic Strategy in Generalized Pustular Psoriasis"*
**作者**: Bachelez H, et al.
**摘要**: 研究评估了抗IL-36受体单克隆抗体(如Imsidolimab)在泛发性脓疱型银屑病(GPP)患者中的疗效，结果显示快速且持久的症状缓解，证实靶向IL-36受体是治疗GPP的有效策略。
2. **文献名称**: *"IL-36RN Mutations Affect Protein Expression and Function: Insights from Antibody-Mediated Detection in Inflammatory Skin Diseases"*
**作者**: Marrakchi S, et al.
**摘要**: 通过特异性抗体检测发现，IL36RN基因突变导致IL-36受体拮抗剂(IL-36Ra)表达缺失或功能异常，进而引发皮肤过度炎症反应，为GPP的病理机制提供分子基础。
3. **文献名称**: *"Neutralizing Anti-IL-36 Antibodies Attenuate Inflammation in Experimental Psoriasis Models"*
**作者**: Tortola L, et al.
**摘要**: 在小鼠银屑病模型中，中和性抗IL-36细胞因子抗体(靶向IL-36α/β/γ)显著抑制皮肤炎症和病理损伤，验证IL-36信号通路作为潜在治疗靶点。
**备注**：IL36RN本身编码天然拮抗剂蛋白(IL-36Ra)，直接针对IL36RN的抗体研究较少，上述文献主要涉及靶向IL-36受体或细胞因子的治疗性抗体研究，或利用抗体检测IL-36Ra的病理作用。
The IL36RN gene encodes the interleukin-36 receptor antagonist (IL-36Ra), a key regulatory protein in the IL-1 cytokine family. IL-36Ra functions as a natural inhibitor of pro-inflammatory IL-36 cytokines (IL-36α, β, γ) by competitively binding to the IL-36 receptor (IL-36R), thereby modulating skin and systemic inflammatory responses. Mutations in IL36RN are strongly linked to autoinflammatory skin disorders, particularly generalized pustular psoriasis (GPP) and its variants, where loss-of-function mutations lead to uncontrolled IL-36 signaling, neutrophil infiltration, and severe epidermal inflammation.
Antibodies targeting IL36RN or its pathway have emerged as critical tools in research and therapeutics. Diagnostic antibodies aid in detecting IL-36Ra expression levels in tissues or serum, helping to identify IL36RN-related pathologies. Therapeutic monoclonal antibodies (e.g., spesolimab, imsidolimab) indirectly address IL36RN dysfunction by neutralizing IL-36R or IL-36 cytokines, showing efficacy in clinical trials for GPP. Research-grade IL36RN antibodies are used to elucidate molecular mechanisms in keratinocyte-mediated inflammation, cytokine crosstalk, and genetic susceptibility to pustular diseases. These advancements highlight IL36RN as both a biomarker and therapeutic target in IL-36-driven inflammatory conditions.
×
